Literature DB >> 12372503

bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.

Joshua T Ayers1, Linda P Dwoskin, A Gabriela Deaciuc, Vladimir P Grinevich, Jun Zhu, Peter A Crooks.   

Abstract

A series of bis-nicotinium, bis-pyridinium, bis-picolinium, bis-quinolinium and bis-isoquinolinium compounds was evaluated for their binding affinity at nicotinic acetylcholine receptors (nAChRs) using rat brain membranes. N,N'-Decane-1,12-diyl-bis-nicotinium diiodide (bNDI) exhibited the highest affinity for [(3)H]nicotine binding sites (K(i)=330 nM), but did not inhibit [(3)H]methyllycaconitine binding (K(i) >100 microM), indicative of an interaction with alpha4beta2*, but not alpha7* receptor subtypes, respectively. Also, bNDI inhibited (IC(50)=3.76 microM) nicotine-evoked (86)Rb(+) efflux from rat thalamic synaptosomes, indicating antagonist activity at alpha4beta2* nAChRs. N,N'-Dodecane-1,12-diyl-bis-quinolinium dibromide (bQDDB) exhibited highest affinity for [(3)H]methyllycaconitine binding sites (K(i)=1.61 microM), but did not inhibit [(3)H]nicotine binding (K(i)>100 microM), demonstrating an interaction with alpha7*, but not alpha4beta2* nAChRs. Thus, variation of N-n-alkyl chain length together with structural modification of the azaaromatic quaternary ammonium moiety afforded selective antagonists for the alpha4beta2* nAChR subtype, as well as ligands with selectivity at alpha7* nAChRs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372503     DOI: 10.1016/s0960-894x(02)00687-x

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

2.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

3.  Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.

Authors:  Roger L Papke; Linda P Dwoskin; Peter A Crooks; Guangrong Zheng; Zhenfa Zhang; J Michael McIntosh; Clare Stokes
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

4.  bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.

Authors:  Thomas E Wooters; Andrew M Smith; Marharyta Pivavarchyk; Kiran B Siripurapu; J Michael McIntosh; Zhenfa Zhang; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 5.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

6.  Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine.

Authors:  Amanda M Struthers; Jamie L Wilkinson; Linda P Dwoskin; Peter A Crooks; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2009-09-22       Impact factor: 3.533

7.  Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.

Authors:  Werner J Geldenhuys; Vamshi K Manda; Rajendar K Mittapalli; Cornelis J Van der Schyf; Peter A Crooks; Linda P Dwoskin; David D Allen; Paul R Lockman
Journal:  Bioorg Med Chem Lett       Date:  2009-12-28       Impact factor: 2.823

8.  Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  J Enzyme Inhib Med Chem       Date:  2009-02       Impact factor: 5.051

9.  Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Guangrong Zheng; Sangeetha P Sumithran; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

10.  Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.

Authors:  Guangrong Zheng; Zhenfa Zhang; Marharyta Pivavarchyk; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-18       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.